In terms of clinical advantages, Bcl-2 inhibitors have been shown to be uniquely safe and well established in the treatment of hematologic malignancies such as chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and follicular lymphoma (FL) [87]. This evidence concerns the gene BCL2 and mantle cell lymphoma.